Medtronic plc (MDT)
We compared 5 Dividend Aristocrats, this one came out on top
A quarter of a century of increasing dividends is a hell of a way to generate some passive income. Enter Dividend Aristocrats.
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, improving operating margins and capital allocation. Recent results show robust cardiovascular growth and strong shareholder returns, with continued buybacks expected post-spin-off.
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
Medtronic plc (MDT) Q4 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q4 2025 Earnings Conference Call May 21, 2025 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head of IR Geoff Martha - Chairman and CEO Que Dallara - EVP & President, Diabetes Thierry Pieton - CFO Sean Salmon - EVP and President of Cardiovascular Portfolio Brett Wall - EVP and President of Neuroscience Portfolio Conference Call Participants Travis Steed - Bank of America Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore Joanne Weunsch - Citi Matt Taylor - Jefferies Matt Miksic - Barclays Danielle Antalffy - UBS Shagun Singh - RBC Operator Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us for our Fiscal ‘25 Fourth Quarter Video Earnings Webcast.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended April 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic to split off its fast-growing diabetes business to unlock its value
The new diabetes company will be predominantly business-to-consumer, while Medtronic's model was more business-to-business.
Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates
Medtronic (MDT) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.46 per share a year ago.
Medtronic to Separate Diabetes Business
The medical device maker has been working to turn around the division over the last few years.
Will Medtronic's Earnings Move The Stock?
Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announcements in 53% of instances.
What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Continue to Hold Medtronic Stock in Your Portfolio Now?
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session.
